UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect

Neoplasia (New York, N.Y.), 2019-02, Vol.21 (2), p.159-171

2019

Volltextzugriff (PDF)

Therapeutic targeting of the hypoxic tumour microenvironment

Nature reviews. Clinical oncology, 2021-12, Vol.18 (12), p.751-772

2021

Volltextzugriff (PDF)

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids

PLoS computational biology, 2018-10, Vol.14 (10), p.e1006469-e1006469

2018

Volltextzugriff (PDF)

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides

Journal of medicinal chemistry, 2018-02, Vol.61 (3), p.1241-1254

2018

Volltextzugriff (PDF)

Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia

International journal of radiation biology, 2019-12, Vol.95 (12), p.1597-1612

2019

Volltextzugriff (PDF)

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104

PloS one, 2011-08, Vol.6 (8), p.e23108

2011

Volltextzugriff (PDF)

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

Cancer research (Chicago, Ill.), 2015-10, Vol.75 (19), p.4211-4223

2015

Volltextzugriff (PDF)

Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review

Biomaterials, 2016-04, Vol.85, p.152-167

2016

Volltextzugriff (PDF)

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361

Biochemical pharmacology, 2019-11, Vol.169, p.113641, Article 113641

2019

Volltextzugriff (PDF)

Targeting hypoxia in cancer therapy

Nature reviews. Cancer, 2011-06, Vol.11 (6), p.393-410

2011

Volltextzugriff (PDF)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors

Molecules (Basel, Switzerland), 2019-04, Vol.24 (8), p.1559

2019

Volltextzugriff (PDF)

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Cancer research (Chicago, Ill.), 2010-02, Vol.70 (4), p.1573-1584

2010

Volltextzugriff (PDF)

Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models

Molecular oncology, 2024-08, Vol.18 (8), p.1885-1903

2024

Volltextzugriff (PDF)

FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells

Biochemical journal, 2013-05, Vol.452 (1), p.79-86

2013

Volltextzugriff (PDF)

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

Clinical cancer research, 2007-07, Vol.13 (13), p.3922-3932

2007

Volltextzugriff (PDF)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Molecules (Basel, Switzerland), 2020-10, Vol.25 (21), p.4888

2020

Volltextzugriff (PDF)

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures

Frontiers in pharmacology, 2018-09, Vol.9, p.1013

2018

Volltextzugriff (PDF)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine

British journal of cancer, 2016-05, Vol.114 (10), p.1071-1077

2016

Volltextzugriff (PDF)

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

BMC cancer, 2011-10, Vol.11 (1), p.432-432, Article 432

2011

Volltextzugriff (PDF)

Endovascular removal of a large free-floating thrombus of the descending thoracic aorta using the AngioVac system

Journal of vascular surgery cases and innovative techniques, 2024-06, Vol.10 (3), p.101460, Article 101460

2024

Volltextzugriff (PDF)

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

BMC cancer, 2012-10, Vol.12 (1), p.496-496, Article 496

2012

Volltextzugriff (PDF)

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors

Molecules (Basel, Switzerland), 2019-07, Vol.24 (14), p.2524

2019

Volltextzugriff (PDF)

Oxygen Dependence and Extravascular Transport of Hypoxia-Activated Prodrugs: Comparison of the Dinitrobenzamide Mustard PR-104A and Tirapazamine

International journal of radiation oncology, biology, physics, 2007-10, Vol.69 (2), p.560-571

2007

Volltextzugriff (PDF)

Characterization of a smart pH-cleavable PEG polymer towards the development of dual pH-sensitive liposomes

International journal of pharmaceutics, 2018-09, Vol.548 (1), p.288-296

2018

Volltextzugriff (PDF)

PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation

Pharmaceutical research, 2018-08, Vol.35 (8), p.154-13, Article 154

2018

Volltextzugriff (PDF)

1 – 25 von 5.379

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.669)
Mit Volltextzugriff
(4.383)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.631)
Life Sciences & Biomedicine
(2.825)
Humans
(2.251)
Female
(1.324)
Male
(1.312)
Biological And Medical Sciences
(1.000)
Medical Sciences
(783)
Animals
(749)
Adult
(740)
Middle Aged
(715)
Aged
(530)
Physical Sciences
(496)
Technology
(335)
Adolescent
(294)
Surgery
(275)
Risk Factors
(270)
General & Internal Medicine
(262)
Mice
(260)
Chemistry
(258)
Fundamental And Applied Biological Sciences. Psychology
(256)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.865)
EZB Electronic Journals Library
(2.245)
IngentaConnect
(2.007)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(1.875)
NUS Single-Journal Subscriptions
(1.597)
Elsevier ScienceDirect Journals Complete
(982)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(705)
IngentaConnect Journals
(643)
Wiley Online Library Journals Frontfile Complete
(575)
JSTOR
(468)
Wiley Online Library Full Collection 2018
(415)
SpringerLink
(242)
Nature
(233)
Oxford journals
(225)
Taylor & Francis
(196)
Ebook Central Perpetual and DDA
(186)
Taylor & Francis Journals
(179)
Taylor & Francis Online
(176)
eBooks on EBSCOhost
(173)
Nexis Uni
(169)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(36)
... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect

Therapeutic targeting of the hypoxic tumour microenvironment

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides

Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361

Targeting hypoxia in cancer therapy

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models

FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Endovascular removal of a large free-floating thrombus of the descending thoracic aorta using the AngioVac system

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors

Oxygen Dependence and Extravascular Transport of Hypoxia-Activated Prodrugs: Comparison of the Dinitrobenzamide Mustard PR-104A and Tirapazamine

Characterization of a smart pH-cleavable PEG polymer towards the development of dual pH-sensitive liposomes

PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation

Suchergebnisse filtern